Hannah R Mathew1, May Y Choi2, Michael D Parkins2, Marvin J Fritzler3. 1. Department of Biological Sciences, University of Calgary, Calgary, AB, Canada. 2. Cumming School of Medicine, University of Calgary, 3330 Hospital Dr. NW, Calgary, AB, T2N 4N1, Canada. 3. Cumming School of Medicine, University of Calgary, 3330 Hospital Dr. NW, Calgary, AB, T2N 4N1, Canada. fritzler@ucalgary.ca.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the development of life-threatening COVID-19 are believed to disproportionately affect certain at-risk populations. However, it is not clear whether individuals with cystic fibrosis (CF) are at a higher risk of COVID-19 or its adverse consequences. Recurrent respiratory viral infections are often associated with perturbation and pulmonary exacerbations of CF as evidenced by the significant morbidity observed in CF individuals during the 2009 H1N1 pandemic. The primary goal of this review was to systematically survey published accounts of COVID-19 in CF and determine if individuals with CF are disproportionally affected by SARS-CoV-2 and development of COVID-19. METHODS: We conducted a systematic literature search using EMBASE and Medline between April 28 and December 10, 2020. Six evaluable studies reporting on a total of 339 individuals with CF who developed COVID-19 were included in this study. RESULTS: We found that although individuals with CF generally experience acute exacerbations of lung disease from infectious agents, COVID-19 incidence estimates in CF appear to be lower than in the general population. However, there are reports of subsets of CF, such as those who had organ transplants, that may experience a more severe COVID-19 course. Potential protective mechanisms in the CF population include pre-pandemic social isolation practices, infection prevention and control knowledge, altered expression of angiotensin-converting enzyme, and the use of certain medications. CONCLUSIONS: Although individuals with CF are at risk of acute exacerbations often precipitated by respiratory tract viral infections, published evidence to date indicated that individuals with CF do not experience higher risks of contracting SARS-CoV-2 infection. However, there is evidence that some subsets within the CF population, including those post-transplantation, may experience a more severe clinical course. As SARS-CoV-2 variants are identified and the pandemic goes through additional waves of disease outbreaks, ongoing monitoring of the risk of COVID-19 in individuals with CF is required.
BACKGROUND:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the development of life-threatening COVID-19 are believed to disproportionately affect certain at-risk populations. However, it is not clear whether individuals with cystic fibrosis (CF) are at a higher risk of COVID-19 or its adverse consequences. Recurrent respiratoryviral infections are often associated with perturbation and pulmonary exacerbations of CF as evidenced by the significant morbidity observed in CF individuals during the 2009 H1N1 pandemic. The primary goal of this review was to systematically survey published accounts of COVID-19 in CF and determine if individuals with CF are disproportionally affected by SARS-CoV-2 and development of COVID-19. METHODS: We conducted a systematic literature search using EMBASE and Medline between April 28 and December 10, 2020. Six evaluable studies reporting on a total of 339 individuals with CF who developed COVID-19 were included in this study. RESULTS: We found that although individuals with CF generally experience acute exacerbations of lung disease from infectious agents, COVID-19 incidence estimates in CF appear to be lower than in the general population. However, there are reports of subsets of CF, such as those who had organ transplants, that may experience a more severe COVID-19 course. Potential protective mechanisms in the CF population include pre-pandemic social isolation practices, infection prevention and control knowledge, altered expression of angiotensin-converting enzyme, and the use of certain medications. CONCLUSIONS: Although individuals with CF are at risk of acute exacerbations often precipitated by respiratory tract viral infections, published evidence to date indicated that individuals with CF do not experience higher risks of contracting SARS-CoV-2 infection. However, there is evidence that some subsets within the CF population, including those post-transplantation, may experience a more severe clinical course. As SARS-CoV-2 variants are identified and the pandemic goes through additional waves of disease outbreaks, ongoing monitoring of the risk of COVID-19 in individuals with CF is required.
Authors: Nicholas W Keiser; Susan E Birket; Idil A Evans; Scott R Tyler; Adrianne K Crooke; Xingshen Sun; Weihong Zhou; Joseph R Nellis; Elizabeth K Stroebele; Kengyeh K Chu; Guillermo J Tearney; Mark J Stevens; J Kirk Harris; Steven M Rowe; John F Engelhardt Journal: Am J Respir Cell Mol Biol Date: 2015-06 Impact factor: 6.914
Authors: Rishi K Wadhera; Priya Wadhera; Prakriti Gaba; Jose F Figueroa; Karen E Joynt Maddox; Robert W Yeh; Changyu Shen Journal: JAMA Date: 2020-06-02 Impact factor: 56.272
Authors: Matthew J Cummings; Matthew R Baldwin; Darryl Abrams; Samuel D Jacobson; Benjamin J Meyer; Elizabeth M Balough; Justin G Aaron; Jan Claassen; LeRoy E Rabbani; Jonathan Hastie; Beth R Hochman; John Salazar-Schicchi; Natalie H Yip; Daniel Brodie; Max R O'Donnell Journal: Lancet Date: 2020-05-19 Impact factor: 79.321
Authors: Mark J Hoegger; Anthony J Fischer; James D McMenimen; Lynda S Ostedgaard; Alex J Tucker; Maged A Awadalla; Thomas O Moninger; Andrew S Michalski; Eric A Hoffman; Joseph Zabner; David A Stoltz; Michael J Welsh Journal: Science Date: 2014-08-15 Impact factor: 47.728
Authors: Parag Goyal; Justin J Choi; Laura C Pinheiro; Edward J Schenck; Ruijun Chen; Assem Jabri; Michael J Satlin; Thomas R Campion; Musarrat Nahid; Joanna B Ringel; Katherine L Hoffman; Mark N Alshak; Han A Li; Graham T Wehmeyer; Mangala Rajan; Evgeniya Reshetnyak; Nathaniel Hupert; Evelyn M Horn; Fernando J Martinez; Roy M Gulick; Monika M Safford Journal: N Engl J Med Date: 2020-04-17 Impact factor: 176.079
Authors: Virginia Lotti; Flavia Merigo; Anna Lagni; Andrea Di Clemente; Marco Ligozzi; Paolo Bernardi; Giada Rossini; Ercole Concia; Roberto Plebani; Mario Romano; Andrea Sbarbati; Claudio Sorio; Davide Gibellini Journal: Cells Date: 2022-04-15 Impact factor: 6.600
Authors: Anurag Verma; Noah L Tsao; Lauren O Thomann; Yuk-Lam Ho; Sudha K Iyengar; Shiuh-Wen Luoh; Rotonya Carr; Dana C Crawford; Jimmy T Efird; Jennifer E Huffman; Adriana Hung; Kerry L Ivey; Michael G Levin; Julie Lynch; Pradeep Natarajan; Saiju Pyarajan; Alexander G Bick; Lauren Costa; Giulio Genovese; Richard Hauger; Ravi Madduri; Gita A Pathak; Renato Polimanti; Benjamin Voight; Marijana Vujkovic; Seyedeh Maryam Zekavat; Hongyu Zhao; Marylyn D Ritchie; Kyong-Mi Chang; Kelly Cho; Juan P Casas; Philip S Tsao; J Michael Gaziano; Christopher O'Donnell; Scott M Damrauer; Katherine P Liao Journal: PLoS Genet Date: 2022-04-28 Impact factor: 6.020
Authors: Iustina Violeta Stan; Victor Daniel Miron; Ioana Alexandra Vangheli; Radu Marian Gheorghiu; Anca Streinu-Cercel; Oana Săndulescu; Mihai Craiu Journal: Diagnostics (Basel) Date: 2022-01-07
Authors: Anke Jaudszus; Mariya Pavlova; Marius Rasche; Michael Baier; Anne Moeser; Michael Lorenz Journal: BMC Pulm Med Date: 2022-03-24 Impact factor: 3.317